article thumbnail

Dapagliflozin approved for heart failure across LVEFs

European Pharmaceutical Review

AstraZeneca’s dapagliflozin is an oral, once-daily selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2). AstraZeneca’s oral dapagliflozin drug. It is already approved in Great Britain for the treatment of insufficiently controlled type 2 diabetes (T2D), symptomatic chronic HFrEF and chronic kidney disease (CKD).

article thumbnail

Improving Patient Outcomes with Immersive Learning

Infuse Medical

VR headsets transport users entirely into a simulated world, while AR overlays blend digital elements with the physical environment. Learners are fully immersed in these virtual environments, allowing them to actively engage with the material and experience concepts in a firsthand manner.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

sales, medical science liaisons, etc.). Outside of the frail and elderly, high-risk patients could also be those who are unable to reliably practice social distancing because of crowded living conditions, inability to stay home if they are essential service workers, and/or the need to take public transportation regularly.

article thumbnail

From Europe To The U.S.: A Medtech Executive’s Career Chronicle With Fred Colen

Evolve Your Success

In the end, I decided to become an engineer but from the get-go specialized in medical technology. They allowed me to do some classes in medical science, which was very nice. I got going from the get-go in medical technology. I was inspired by it. Before you continue that, we’ve got to let the audience know what you do.